D. Piccin

发表

miR‐15a and miR‐16‐1 down‐regulation in pituitary adenomas

Arianna Bottoni, A. Bottoni, M. Zatelli, 2005, Journal of cellular physiology.

Identification of differentially expressed microRNAs by microarray: A possible role for microRNA genes in pituitary adenomas

George A Calin, Massimo Negrini, Arianna Bottoni, 2007, Journal of cellular physiology.

Proteasomes and RARS modulate AIMP1/EMAP II secretion in human cancer cell lines

A. Bottoni, M. Zatelli, D. Piccin, 2007, Journal of cellular physiology.

Antiproliferative effects of somatostatin analogs in pituitary adenomas

M. Bondanelli, M. Zatelli, D. Piccin, 2006, Pituitary.

Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.

G. Maira, A. Pontecorvi, A. Bianchi, 2007, Endocrine-related cancer.

Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.

A. Bottoni, M. Culler, M. Bondanelli, 2005, Journal of molecular endocrinology.

Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion.

M. Culler, M. Zatelli, D. Piccin, 2003, The Journal of clinical endocrinology and metabolism.

Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line.

M. Culler, John E. Taylor, M. Bondanelli, 2002, Biochemical and biophysical research communications.

SRC homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma.

A. Bottoni, M. Zatelli, D. Piccin, 2005, Endocrinology.

Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro.

A. Bottoni, M. Culler, L. Cavazzini, 2004, The Journal of clinical endocrinology and metabolism.

Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid.

D. Rubello, N. Sicolo, M. Culler, 2005, The Journal of clinical endocrinology and metabolism.

An in vivo OctreoScan-negative adrenal pheochromocytoma expresses somatostatin receptors and responds to somatostatin analogs treatment in vitro.

M. Culler, M. Bondanelli, M. Zatelli, 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT.

J. Taylor, M. Culler, D. Piccin, 2002, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Role of complex cyclin d1/cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro.

A. Bottoni, M. Culler, M. Zatelli, 2006, Endocrinology.

Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression.

M. Bondanelli, M. Zatelli, D. Piccin, 2007, Endocrine-related cancer.

Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.

M. Pelizzo, A. Bottoni, M. Culler, 2006, The Journal of clinical endocrinology and metabolism.

Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism.

A. Bottoni, M. Bondanelli, M. Zatelli, 2005, The Journal of clinical endocrinology and metabolism.